The patients were surveyed by quetionnaire and asked whether they preferred the fentanyl buccal tablet
or their previous breakthrough pain medicine, and 158 patients (80%) said they preferred fentanyl buccal tablets
In September 2006, the fentanyl buccal tablet
formulation was approved in the United States under the trade name FENTORA(R) (fentanyl buccal tablet
acyclovir), 50mg Muco-Adhesive Buccal Tablet
is indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adults.
market in October 2006, and is the first tablet formulation of fentanyl and the first buccal tablet
approved for cancer-related breakthrough pain.
The ongoing phase II trial with clonidine Lauriad([R]) was also presented: y A phase II, multicentre, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of Clonidine Lauriad([R]) 50 g and 100 g mucoadhesive buccal tablet
(MBT) applied once daily in the prevention and treatment of chemoradiotherapy-induced oral mucositis in patients with head and neck cancer e.
This international multicenter randomized, double-blind, placebo-controlled study compared the efficacy and safety of a single dose of acyclovir Lauriad([R]) 50mg Mucoadhesive Buccal Tablet
(MBT) versus matching placebo in 1727 randomized and 775 treated patients suffering from recurrent herpes labialis.
collectively "Watson") pertaining to Cephalon's FENTORA fentanyl buccal tablet
miconazole MBT: Mucoadhesive Buccal Tablet
, Loramyc([R]) in Europe
Results on two European phase III studies were also presented in two posters entitled: "Miconazole Mucoadhesive Buccal Tablet
for the Treatment of Oropharyngeal Candidiasis in Head and Neck Cancer Patients" and "Evaluation of Miconazole MucoAdhesive Buccal Tablet
: a novel once daily antifungal treatment for Oropharyngeal Candidiasis".
Oravig, which adheres to the gum, utilizes innovative buccal tablet
technology enabling once-daily dosing that delivers miconazole directly at the local site of infection throughout the day with minimal systemic absorption.
This multicenter randomized, double-blind, placebo controlled study compared the efficacy and safety of a single dose acyclovir Lauriad[R] 50mg Mucoadhesive Buccal Tablet
(MBT) versus matching placebo in patients suffering from recurrent oro-facial herpes.
Miconazole Lauriad[R] delivers the antifungal miconazole via a mucoadhesive buccal tablet
that is designed to enable once-daily dosing of the active ingredient at the site of infection.